Physician profile
Viraj Jayesh Mehta
NPI 1992047617
$2,323.34
in general payments reported to CMS, 2019-2025
17 companies · $935 in 2025
The $935 reported for 2025 was more than what 76% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $116 · 2021: $16.79 · 2022: $27.83 · 2023: $586 · 2024: $509 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $342.51 | 2022-2023 | Tepezza |
| Amgen INC. | $310.90 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $212.57 | 2024-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol, Miebo |
| Sight Sciences, INC. | $199.31 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $165.28 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $132.03 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $127.88 | 2025 | Oxervate |
| Genentech USA, INC. | $126.88 | 2025 | Susvimo |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 | |
| Sun Pharmaceutical Industries INC. | $116.16 | 2025 | |
| Glaukos Corporation | $111.28 | 2025 | Photrexa Viscous and Photrexa, Idosetr |
| Novartis Pharmaceuticals Corporation | $99.04 | 2019 | |
| Abbvie INC. | $91.84 | 2023 | |
| Harrow Eye, LLC | $70.59 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $51.09 | 2023-2024 | Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $32.83 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viraj Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.